Berinert® (C1 esterase inhibitor [human])

Covered: Berinert is covered for treatment of acute HAE attacks (FDA‑approved) and for compendial prophylaxis in patients with HAE type I or II due to C1‑INH deficiency; other indications are not supported. Key requirements: baseline labs showing functional C1‑INH <50% of normal and low serum C4, prescription by or consultation with an HAE specialist, dosing 20 IU/kg IV (no more than once daily), initial approvals for 12 months, and reauthorization requires documented clinical benefit (reduced attack frequency/severity/duration or rapid/complete symptom relief).

"Berinert is indicated for the treatment of acute attacks of Hereditary Angioedema (HAE)."

Sign up to see full coverage criteria, indications, and limitations.